Sectoral Asset Management and Andera Partners led an $80m Series B round in Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, with participation from ATEM Capital. "We are very pleased to expand our high-quality syndicate with the addition of these new North American and European investors, and we are highly appreciative of the continued support from our existing investors," Thierry Abribat, Amolyt Pharma Founder, and CEO.